Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Qyuns Therapeutics CoHKSE:02509 -1.84%9 Interest Coverage is 40.76 as of Dec. 2025, which is 135% above its 10-year median of 17.33. GuruFocus rates HKSE:02509 with a GF Score™ of 9/100. The stock has 5 warning signs investors should review. Among 373 Biotechnology companies, Qyuns Therapeutics Co ranks worse than 68.63% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Qyuns Therapeutics Co's
Operating Income
for the
six
months ended in Dec. 2025 was HK$391.2 Mil. Qyuns Therapeutics Co's Interest Expense for the
six
months ended in Dec. 2025 was HK$-9.6 Mil.
Qyuns Therapeutics Co's interest coverage for the quarter that ended in Dec. 2025 was 40.76.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for Qyuns Therapeutics Co's Interest Coverage or its related term are showing as below:
HKSE:02509'
s Interest Coverage Range Over the Past 10 Years
Min: 17.33 Med: 17.33 Max: 17.45
Current: 17.45
HKSE:02509's Interest Coverage is ranked worse than 68.63% of 373
companies
in the Biotechnology industry
Industry Median: 99.7
vs HKSE:02509: 17.45
Qyuns Therapeutics Co (HKSE:02509) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Qyuns Therapeutics Co Interest Coverage Related Terms
Qyuns Therapeutics Co Interest Coverage Historical Data
* Premium members only.
The historical data trend for Qyuns Therapeutics Co's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
HKSE:02509 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, Qyuns Therapeutics Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qyuns Therapeutics Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Qyuns Therapeutics Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Qyuns Therapeutics Co's Interest Coverage falls into.
Qyuns Therapeutics Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qyuns Therapeutics Co (HKSE:02509) has a Interest Coverage of 40.76 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qyuns Therapeutics Co and its competitors. This is 135% above median its historical median of 17.33. Over the past decade, Qyuns Therapeutics Co's Interest Coverage has ranged from 17.33 to 17.45. According to the industry distribution chart, Qyuns Therapeutics Co ranks #256 out of 373 companies in the Biotechnology industry, placing it in the top 68.6%.
Is Qyuns Therapeutics Co's Interest Coverage too high?
Qyuns Therapeutics Co's current Interest Coverage of 40.76 is 135% above median its 10-year median of 17.33. Over the past 10 years, this metric has ranged from a low of 17.33 to a high of 17.45. The Biotechnology industry median Interest Coverage is 99.70. Qyuns Therapeutics Co's value of 40.76 is 59.1% below this industry median. Based on the distribution chart, Qyuns Therapeutics Co ranks #256 out of 373 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Qyuns Therapeutics Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Qyuns Therapeutics Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Qyuns Therapeutics Co ranks #256 out of 373 companies for Interest Coverage. This places Qyuns Therapeutics Co in the lower half of its industry. The industry median Interest Coverage is 99.70. Qyuns Therapeutics Co's value of 40.76 is 59.1% below this benchmark. Historically, Qyuns Therapeutics Co's own Interest Coverage has ranged from 17.33 to 17.45 over the past decade. While the company's 10-year median is 17.33 vs. the industry median of 99.70, Qyuns Therapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 99.70, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Qyuns Therapeutics Co's current Interest Coverage of 40.76 is 59.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Qyuns Therapeutics Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 99.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Qyuns Therapeutics Co's current Interest Coverage is 40.76, which is 135% above median its own 10-year median of 17.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qyuns Therapeutics Co stock overvalued right now?
Qyuns Therapeutics Co (HKSE:02509) has a current Interest Coverage of 40.76. The current Interest Coverage is 40.76, which is 135% above median its 10-year median of 17.33 and 59.1% below the Biotechnology industry median of 99.70. Qyuns Therapeutics Co's overall GF Score™ is 9/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Qyuns Therapeutics Co (HKSE:02509), the current Interest Coverage is 40.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Qyuns Therapeutics Co Ltd is a clinical-stage biotech company focused on biologic therapies for autoimmune and allergic diseases, with a self-developed drug pipeline. It has built a pipeline that covers the four disease areas in the field, including skin, rheumatic, respiratory, and digestive diseases. The group is principally engaged in the research and development, manufacturing, and commercialisation of biologic therapies for autoimmune and allergic diseases. Key revenue is generated from the PRC.
9GF Score
Get the complete analysis for HKSE:02509
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02509 has been successfully added to your 
